Dear Colleagues,
Alzheimer's disease and other neurodegenerative diseases have been widely investigated from bench to bedside. Although the putative hallmarks have been established for decades, there remains an important mismatch between pre-clinical and clinical achievements. In particular, the failure of monoclonal antibodies and other strategies that target amyloid-Beta can be used as a paradigmatic example.
Here, we welcome alternative hypotheses and preclinical or clinical studies that use alternative strategies to the fruitless efforts so far based on the classical, protein-based approaches. We also welcome novel approaches that help to unravel what has so far been missed regarding protein misfolding, precocious phases of the diseases, and non-neuronal cells.
Dr. Ciro De Luca
Guest Editor
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 500 USD. Submitted manuscripts should be well formatted in good English.